Digesting Caronia
This article was originally published in RPM Report
Executive Summary
A December appellate court ruling in an off-label promotion case prompted headlines about sweeping implications for FDA’s regulatory authority. How does the ruling look four months later?
You may also be interested in...
Acknowledging Caronia: FDA Takes The First Step To Rethinking Off-Label Policy
FDA has gotten past the denial phase and now is listening to ideas on how to balance the need to preserve the integrity of the regulatory process with evolving interpretations of the First Amendment as it applies to commercial speech. That is slow but important progress – but towards what goal?
Risperdal Settlement Shows False Claims Act Prosecutions Still Have Teeth After Caronia
A $2.2 billion settlement prompts another round of headlines about the pharmaceutical industry's marketing practices -- and no apparent indication that the Caronia ruling is changing the way prosecutors (and the public) perceive off-label promotion.
FDA Off-Label Citations Disappear In Post-Caronia Enforcement Letters
Office of Prescription Drug Promotion letters post-Caronia fail to cite off-label promotion, in contrast to previous years when about one-third to one-half of warning and untitled letters scolded companies for off-label violations.